Zhejiang Jiangbei Pharmaceutical Co., Ltd.
As of 18 November 2026, for the company name Zhejiang Jiangbei Pharmaceutical Co., Ltd. as recorded, the chemical-drug catalogue lists 9 active records with this name as holder; 12 active API registrations list this name as first registered company.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.
Drug filings
19 acceptance records as first applicant, grouped into 14 source drug names. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Ezetimibe Tablets 1 records · Latest accepted 2026/10/14
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2602544 | Generic | 2026/10/14 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
Probucol Tablets 1 records · Latest accepted 2026/08/10
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2601948 | Generic | 2026/08/10 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
Dapagliflozin Tablets 2 records · Latest accepted 2026/08/10
Generic · 2
Ticagrelor Tablets 2 records · Latest accepted 2025/12/10
Generic · 2
Glucosamine Sulfate Capsules 1 records · Latest accepted 2025/11/29
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2504116 | Generic | 2025/11/29 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
Ezetimibe and Atorvastatin Calcium Tablets(II) 1 records · Latest accepted 2025/10/14
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2503643 | Generic | 2025/10/14 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
Empagliflozin Tablets 1 records · Latest accepted 2025/06/17
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2502147 | Generic | 2025/06/17 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
Benzbromarone Tablets 1 records · Latest accepted 2025/04/28
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2501591 | Generic | 2025/04/28 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
Bisoprolol Fumarate and Amlodipine Besylate Tablets 1 records · Latest accepted 2025/03/10
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2500995 | Generic | 2025/03/10 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
Atorvastatin Calcium Tablets 2 records · Latest accepted 2024/12/17
Generic · 2
Trazodone Hydrochloride Tablets 1 records · Latest accepted 2024/08/30
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2402827 | Generic | 2024/08/30 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
Pioglitazone and Metformin Hydrochloride Tablets 1 records · Latest accepted 2024/06/21
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2401853 | Generic | 2024/06/21 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
Rosuvastatin Calcium Tablets 2 records · Latest accepted 2022/10/11
Supplement · 2
Levetiracetam Tablets 2 records · Latest accepted 2022/04/19
Generic · 2
Changes in the last 90 days
5 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Marketing application approved: 2 applicationsAccepted: 1 applicationNo longer listed under review: 2 applications
- 2026/11/10Marketing application approved
Empagliflozin Tablets
CYHS2502147 · 国药准字H20266571
Fact date: 2026/11/10 · Publication date: 2026/11/13 · Date added to this site: 2026/11/14
View source · Table row 89 ↗ - 2026/11/10Marketing application approved
Benzbromarone Tablets
CYHS2501591 · 国药准字H20266559
Fact date: 2026/11/10 · Publication date: 2026/11/13 · Date added to this site: 2026/11/14
View source · Table row 62 ↗ - 2026/10/28No longer listed under review
Empagliflozin Tablets
CYHS2502147
Fact date: 2026/10/28 · Date added to this site: 2026/10/28
Accepted: 2025/06/17
no longer on the CDE under-review list as of the data cut-off; NMPA published approval-document delivery for this acceptance number on 2026/11/13 (approval no.: 国药准字H20266571; approval date: 2026/11/10) · NMPA source · row 89
NMPA · Table row 89 ↗ View source ↗ - 2026/10/28No longer listed under review
Benzbromarone Tablets
CYHS2501591
Fact date: 2026/10/28 · Date added to this site: 2026/10/28
Accepted: 2025/04/28
no longer on the CDE under-review list as of the data cut-off; NMPA published approval-document delivery for this acceptance number on 2026/11/13 (approval no.: 国药准字H20266559; approval date: 2026/11/10) · NMPA source · row 62
NMPA · Table row 62 ↗ View source ↗ - 2026/10/14Accepted
Ezetimibe Tablets
CYHS2602544
Fact date: 2026/10/14 · Date added to this site: 2026/10/22
View source ↗
Under review
7 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Ezetimibe Tablets | CYHS2602544 | Generic | 2026/10/14 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
| Probucol Tablets | CYHS2601948 | Generic | 2026/08/10 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
| Dapagliflozin Tablets | CYHS2601938 | Generic | 2026/08/10 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
| Dapagliflozin Tablets | CYHS2601937 | Generic | 2026/08/10 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
| Ticagrelor Tablets | CYHS2504240 | Generic | 2025/12/10 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
| Glucosamine Sulfate Capsules | CYHS2504116 | Generic | 2025/11/29 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
| Ezetimibe and Atorvastatin Calcium Tablets(II) | CYHS2503643 | Generic | 2025/10/14 | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
Catalogue holder records
9 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Bisoprolol Fumarate and Amlodipine Besylate Tablets | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | 国药准字H20265149 | 2026/07/14 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 吡格列酮二甲双胍片(I) · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | 国药准字H20264154 | 2026/04/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Atorvastatin Calcium Tablets | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | 国药准字H20264103 | 2026/04/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Atorvastatin Calcium Tablets | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | 国药准字H20264102 | 2026/04/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Trazodone Hydrochloride Tablets | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | 国药准字H20263152 | 2026/01/20 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Levetiracetam Tablets | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | 国药准字H20234363 | 2023/10/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Levetiracetam Tablets | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | 国药准字H20234362 | 2023/10/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rosuvastatin Calcium Tablets | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | 国药准字H20203464 | 2020/09/02 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rosuvastatin Calcium Tablets | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | 国药准字H20203463 | 2020/09/02 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
12 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 瑞舒伐他汀钙 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20220000289 | A | 2023/09/27 | CDE ↗ |
| 磷酸西格列汀 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20210000925 | A | 2024/01/17 | CDE ↗ |
| 磷酸西格列汀 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20210000387 | I | 2021/06/28 | CDE ↗ |
| 利奈唑胺 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20190021444 | I | 2020/01/15 | CDE ↗ |
| 依非韦伦 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20190009799 | A | — | CDE ↗ |
| 辛伐他汀 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20190009704 | A | 2025/04/11 | CDE ↗ |
| 辛伐他汀 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20180001496 | A | 2024/07/30 | CDE ↗ |
| 左乙拉西坦 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20180001065 | A | 2025/11/11 | CDE ↗ |
| 瑞舒伐他汀钙 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20170001629 | A | 2024/05/01 | CDE ↗ |
| 埃索美拉唑钠 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20170001319 | I | — | CDE ↗ |
| 阿托伐他汀钙 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20170000432 | A | 2024/10/24 | CDE ↗ |
| 硫酸氢氯吡格雷 · No verified English name | Zhejiang Jiangbei Pharmaceutical Co., Ltd. | Y20170000089 | I | — | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
2 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Escitalopram Oxalate Tablets | CYHS2101746 | Generic | 2021/09/16 | Guangdong Jiu Rui Technology Kai Fa Co., Ltd. romanized; Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
| Escitalopram Oxalate Tablets | CYHS2101745 | Generic | 2021/09/16 | Guangdong Jiu Rui Technology Kai Fa Co., Ltd. romanized; Zhejiang Jiangbei Pharmaceutical Co., Ltd. | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/18 · Current coverage may be incomplete
- Chemical-drug catalogue
- Last successful update: 2026/11/18
- API registrations
- Last successful update: 2026/11/18
- NMPA drug delivery notices
- Last successful update: 2026/11/19
Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.